SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Novartis AG. (1/1/15). "Press Release: Novartis Completes Divestment of Animal Health Business to Eli Lilly for USD 5.4 Billion". Basel.

Region Region ALL
Organisations Organisation Novartis AG (NYSE: NVS)
  Group Novartis (Group)
  Organisation 2 Novartis Animal Health Division
  Group Eli Lilly (Group)
Products Product animal health
  Product 2 DRUGS–OTC
Index term Index term Novartis–Lilly: investment, 201404–201501 acquisition $5.4b in cash of Novartis Animal Health Divison by Eli Lilly

Novartis announced today that it has completed effective January 1, 2015 the divestment of its Animal Health Division to Eli Lilly and Company (Lilly) for approximately USD 5.4 billion. The completion of this transaction is part of a comprehensive set of transactions announced last April, that will focus Novartis on its three leading businesses of global scale: innovative pharmaceuticals, eye care, and generics.

Deal Terms and Related Information

As a result of today's announcement, Novartis will show in the first quarter of 2015 an exceptional pre-tax gain of approximately USD 4.6 billion.

The Novartis Animal Health results for the full year to December 31, 2014 will be reported under Discontinuing Operations in the Novartis 2014 consolidated financial statements. In 2015, apart from the Animal Health divestment gain, the Consumer Health divisional results will only include the Novartis OTC business.

2013 net sales of Animal Health were approximately USD 1.1 billion, and net sales through Q3 2014 were approximately USD 0.9 billion.


The foregoing release contains forward-looking statements that can be identified by words such as "will," "future," "expected," "to focus," or similar terms, or by express or implied discussions regarding potential future sales or earnings of any of the businesses involved in the announced transactions, or of the Novartis Group, regarding the potential completion of the remaining announced transactions, or regarding any potential strategic benefits, synergies or opportunities as a result of the announced transactions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Novartis will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of the announced transactions. Nor can there be any guarantee that the remaining transactions will be completed in the expected form or within the expected time frame or at all. Neither can there be any guarantee that Novartis or any of the businesses involved in the transactions will achieve any particular future financial results in the future. In particular, management's expectations could be affected by, among other things, the potential that the strategic benefits, synergies or opportunities expected from the transactions may not be realized or may take longer to realize than expected; unexpected regulatory actions or delays or government regulation generally, including an unexpected failure to obtain necessary government approvals for the remaining transactions, or unexpected delays in obtaining such approvals; the potential that any other closing conditions for any of the transactions might not be met; the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; the Company's ability to obtain or maintain proprietary intellectual property protection; global trends toward health care cost containment, including ongoing pricing pressures; general economic and industry conditions, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit

Novartis is on Twitter. Sign up to follow @Novartis at

# # #

Novartis Media Relations
Central media line : +41 61 324 2200

Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)

Liz Power
Novartis Global Media Relations
+1 212 830 2466 (direct)
+1 617 583 3015 (mobile)


For Novartis multimedia content, please visit
For questions about the site or required registration, please contact:

Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257
Isabella Zinck +41 61 324 7188

e-mail: e-mail:

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Record changed: 2017-04-02


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Novartis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSG] – The Business Web Portal 600x80px

» top